Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell Trial – NASDAQ
|
Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell Trial
NASDAQ (RTTNews.com) – Neuralstem Inc. ( CUR ) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at Emory … First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialPR Newswire (press release) |
